CDK4 and neoplasm: While preclinical studies demonstrated the efficacy of CDK4/6 inhibition in Rb-proficient human tumor xenograft models, the introduction of CDK4/6 inhibitors has significantly changed the management of endocrine-resistant ER+ breast cancer [85].